We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AnaptysBio Announces Collaboration with VLST to Generate Novel Antibody Therapeutics
News

AnaptysBio Announces Collaboration with VLST to Generate Novel Antibody Therapeutics

AnaptysBio Announces Collaboration with VLST to Generate Novel Antibody Therapeutics
News

AnaptysBio Announces Collaboration with VLST to Generate Novel Antibody Therapeutics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AnaptysBio Announces Collaboration with VLST to Generate Novel Antibody Therapeutics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AnaptysBio, Inc. has announced a collaboration with VLST Corporation to generate novel multi-antigen specific antibody therapeutics for the treatment of autoimmune and inflammatory disorders. This is the fourth collaboration announced by AnaptysBio during 2010.

“A key objective of this collaboration is to leverage the ability of AnaptysBio’s SHM-Platform™ to select antibodies that bind specifically to multiple target antigens of interest.”

Under the terms of the agreement, AnaptysBio will be responsible for generating novel antibodies using its proprietary somatic hypermutation (SHM) technology platform. Antibodies generated by AnaptysBio will be developed and commercialized by VLST, a Seattle-based biotechnology company focused on the development of therapeutics for autoimmune and inflammatory disorders. AnaptysBio has received an upfront payment to initiate the collaboration and is eligible to receive milestone payments and royalties associated with the development and sale of any products derived from the collaboration.

“A key objective of this collaboration is to leverage the ability of AnaptysBio’s SHM-Platform™ to select antibodies that bind specifically to multiple target antigens of interest,” said Tom Smart, chairman and chief executive officer of AnaptysBio. “Antibodies that bind specifically to multiple antigens are an area of increasing interest to the industry and one of the most exciting areas for novel therapeutic antibody development. We anticipate entering more collaborations because of growing interest in our platform’s ability to naturally evolve antibodies to meet challenging design goals and simultaneously select across multiple parameters for those with the desired properties, such as multi-antigen binding specificity.”
Advertisement